IMAGE

Fig. 3

ID: ZDB-IMAGE-211009-30
Publication: He et al., 2021 - Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss
All Figures: Figures for He et al., 2021

Image

Figure Caption

Fig. 3 Sirolimus, but not trametinib or buparlisib, prevents rapid relapse of <italic>nf1/pten</italic>-mutant melanoma following treatment.

Three-week-old rag2^−/− zebrafish transplanted with pigmented nf1/pten-mutant melanoma cells were treated for 6 days with DMSO, 80 nM trametinib, 2 μM buparlisib, the combination of 80 nM trametinib and 2 μM buparlisib, or 20 μM sirolimus. a, c, e, g, and i Representative zebrafish at the end of the 6-day drug treatment. b, d, f, h, and j Representative zebrafish at 4 days following the end of drug treatment. k Quantification of melanotic nf1/pten-mutant tumor-cell area at the end of the 6-day course of drug treatment (left), and 4 days later (right). ns p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001 by two-tailed, unpaired t-test. Scale bar = 1 mm.

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Oncogene